A Patient-Centric Platform Trial for Precision Oncology
Study on Cancer Patient Data Collection for Treatment Information
Study Overview
Study Details
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
- Conditions: Oncology
-
Gender: All
- Both male and female patients with known or suspected recalcitrant or advanced cancer are eligible to enroll through the Cancer Commons Website
- Patients with any performance status, comorbidity or disease severity are eligible
- Patients or their legally-authorized representative must be willing and able to provide written, informed consent (and assent, if applicable)
- Patients must be a resident of or receiving care within the United States or US territories.
This study investigates a registry platform for cancer patients, focusing on collecting data about their treatments, decisions, and outcomes. The aim is to understand the effectiveness and safety of anti-cancer therapies and supportive care. An observational study is a type of research study where data is collected by observing participants receiving routine care, without changing their treatment, which may focus on people using specific medications or having certain conditions to better understand how treatments work.
Participants will consent to share their medical information, which will be reviewed by a virtual tumor board. This board will help generate personalized treatment options. The study will track patients in their usual treatment settings, collecting data on safety and efficacy outcomes. This information will be used alongside expert judgment and artificial intelligence to improve treatment options.
- Who can participate: Adults with known or suspected advanced cancer can participate. Eligible participants include both males and females, regardless of performance status or disease severity, who can provide informed consent and reside in the United States or its territories.
- Study details: Participants will share their medical data for review to create personalized treatment plans. The study tracks treatment outcomes in usual care settings to gather data on safety and efficacy.